Archives for: September 15th, 2016

Defencath™, an investigational drug product, was granted FDA Fast Track status and is designated as a Qualified Infectious Disease Product.

Written by cormedixadmin on September 15, 2016

Defencath™, an investigational drug product, was granted FDA Fast Track…

Defencath™ , an investigational drug product, is a novel, antimicrobial and antifungal solution being developed for the prevention of catheter-related bloodstream infections (“CRBSIs”) in patients with end-stage renal disease receiving hemodialysis through a central venous catheter.

Written by Developer on August 8, 2016

Defencath™ , an investigational drug product, is a novel, antimicrobial…